SARS-CoV-2 PNEUMONIA
7
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Exo 2 Inhalation
Research Leaders
10 sponsors active, led by Samara State Medical University
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
29%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (7)
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study
Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
Predictors of Respiratory Failure in SARS-Cov-2 Infection
Research Network
Common Treatments
- Exo 2 Inhalation2
- Hydroxychloroquine2
- Exo 1 Inhalation2
- Recombinant Covid19 Vaccine Sf9 Cell1
- Clinical Functional And Radiological Lung Involvement Evolution1
Active Sponsors
- Samara State Medical University2
- Samara Regional Clinical Hospital V.D. Seredavin2
- IRCCS Azienda Ospedaliero-Universitaria di Bologna1
- University of Bologna1
- Washington State University1
Top Investigators
Washington State University
Kootenai Health
Washington State University
Kootenai Health
Related Conditions
- Covid195